CIVATI, AURORA
CIVATI, AURORA
Universita' degli Studi di MILANO
Rifampicin drug monitoring in TB patients: new evidence for increased dosage?
2025 M. Schiuma, M. Colaneri, D. Cattaneo, M. Fusi, A. Civati, M. Galimberti, M.V. Cossu, C. Gervasoni, A. Dolci, A. Riva, S. Antinori, A. Gori, A. Torre
NAT2 Acetylation Status Predicts Hepatotoxicity During Antituberculosis Therapy: Cumulative Risk Analysis of a Multiethnic Cohort
2025 M. Schiuma, S. Dinegro, V. Battini, A. Torre, A. Covizzi, A. Civati, M. Galimberti, I. Mariani, G. Mosini, C. Carnovale, A. Riva, A. Gori, S. Antinori, E. Clementi, S. Radice, S. Cheli
Management of Polypharmacy and Potential Drug-Drug Interactions in Patients with Pulmonary Aspergillosis: A 2-Year Study of a Multidisciplinary Outpatient Clinic
2024 D. Cattaneo, A. Torre, M. Schiuma, A. Civati, G. Casalini, A. Gori, S. Antinori, C. Gervasoni
NAT2 Slow Acetylator Phenotype as a Significant Risk Factor for Hepatotoxicity Caused by Antituberculosis Drugs: Results From a Multiethnic Nested Case-Control Study
2024 S. Cheli, A. Torre, M. Schiuma, C. Montrasio, A. Civati, M. Galimberti, V. Battini, I. Mariani, G. Mosini, C. Carnovale, S. Radice, E. Clementi, A. Gori, S. Antinori
Management of Polypharmacy and Potential Drug–Drug Interactions in Patients with Mycobacterial Infection: A 1-Year Experience of a Multidisciplinary Outpatient Clinic
2023 D. Cattaneo, A. Torre, M. Schiuma, A. Civati, S. Lazzarin, G. Rizzardini, A. Gori, S. Antinori, C. Gervasoni